IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial — 1dHUTCHMED has begun the Phase Ia portion of a global first-in-human trial of HMPL-A830 in patients with advanced or metastatic solid tumors, with the first dose given in China on September 24. The antibody-targeted therapy is designed to deliver a KRAS inhibitor to EGFR-expressing tumors while blocking both KRAS and EGFR signaling; the early-stage study will assess safety, dosing and preliminary anti-tumor activity.

Chris Dalton Starting the first dose in China is practical but the global part will show if it works across populations.

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B — Sep 3, 2026GSK agreed to license Hutchmed’s HMPL-A830, a KRAS-EGFR antibody-drug conjugate, for up to $1.295 billion including $110 million upfront, with global rights outside Mainland China, Hong Kong, Macau and Taiwan while Hutchmed retains development and commercialization duties in those regions. The collaboration targets initial trials in colorectal, pancreatic, and lung cancers, leveraging a dual KRAS-EGFR mechanism to improve efficacy and tolerability.

Jared Kim Dual-targeting KRAS-EGFR is an interesting bet, hope it actually improves tolerability and not just adds complexity.

Experimental pancreatic cancer drug now available in Nebraska — Jul 23, 2026Daraxonrasib, an investigational KRAS-targeting drug, has shown the potential to more than double survival in stage IV pancreatic cancer compared with chemotherapy and is being offered through expanded access programs at Nebraska Medicine, with Ben Sasse publicly discussing his positive response. The FDA has accepted an NDA for daraxonrasib based on phase 3 trial results showing significant improvements in overall survival, progression-free survival, and response rate, signaling a possible breakthrough though not yet FDA approved.